JP2005539067A5 - - Google Patents

Download PDF

Info

Publication number
JP2005539067A5
JP2005539067A5 JP2004536556A JP2004536556A JP2005539067A5 JP 2005539067 A5 JP2005539067 A5 JP 2005539067A5 JP 2004536556 A JP2004536556 A JP 2004536556A JP 2004536556 A JP2004536556 A JP 2004536556A JP 2005539067 A5 JP2005539067 A5 JP 2005539067A5
Authority
JP
Japan
Prior art keywords
peg
binding moiety
antibody
recognition binding
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004536556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005539067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/029059 external-priority patent/WO2004024889A2/en
Publication of JP2005539067A publication Critical patent/JP2005539067A/ja
Publication of JP2005539067A5 publication Critical patent/JP2005539067A5/ja
Withdrawn legal-status Critical Current

Links

JP2004536556A 2002-09-16 2003-09-16 ポリエチレングリコールリンカーを用いる二重特異性分子の産生 Withdrawn JP2005539067A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41173102P 2002-09-16 2002-09-16
PCT/US2003/029059 WO2004024889A2 (en) 2002-09-16 2003-09-16 Production of bispecific molecules using polyethylene glycol linkers

Publications (2)

Publication Number Publication Date
JP2005539067A JP2005539067A (ja) 2005-12-22
JP2005539067A5 true JP2005539067A5 (cg-RX-API-DMAC7.html) 2006-11-02

Family

ID=31994266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004536556A Withdrawn JP2005539067A (ja) 2002-09-16 2003-09-16 ポリエチレングリコールリンカーを用いる二重特異性分子の産生

Country Status (6)

Country Link
US (1) US20060153839A1 (cg-RX-API-DMAC7.html)
EP (1) EP1539811A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005539067A (cg-RX-API-DMAC7.html)
AU (1) AU2003270686A1 (cg-RX-API-DMAC7.html)
CA (1) CA2499075A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004024889A2 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532626A (ja) * 2001-03-15 2004-10-28 エリューシス セラピューティクス,インコーポレーテッド 二重特異性分子のポリクローナル集団、ならびにそれらの産生方法および使用
EP1483383A4 (en) * 2002-02-15 2007-10-24 Cygene Inc METHODS AND COMPOSITIONS FOR THE CLEANING OF PATHOGENS IN VIVO
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003095626A2 (en) * 2002-05-13 2003-11-20 Elusys Therapeutics, Inc. Purified composition of bispecific molecules and methods of production
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
JP2007525446A (ja) * 2003-03-28 2007-09-06 エルシス セラピューティクス, インク. 抗体活性の転換のための方法及び組成物
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20090036327A1 (en) * 2003-07-08 2009-02-05 Trex Enterprises Corp. Method for chemical treatment of porous silicon surface
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
CA2585849A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20060134694A1 (en) * 2004-12-22 2006-06-22 Intel Corporation Methods of protein profiling by thiolation
EP1893241A2 (en) * 2005-04-28 2008-03-05 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗cd30抗体
CN104090095B (zh) 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
EP1968643A2 (en) * 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
DE102006011507A1 (de) 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
EP2064240A2 (en) 2006-09-18 2009-06-03 Xencor, Inc. Optimized antibodies that target hm1.24
US7935345B2 (en) 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
WO2009048494A1 (en) * 2007-07-30 2009-04-16 Trex Enterprises Corporation Method of chemical treatment of porous silicon surfaces
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
EP3153180A1 (en) * 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US9239332B2 (en) 2011-07-11 2016-01-19 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
JP6158090B2 (ja) * 2011-10-31 2017-07-05 ダニエル・ジェイ・カポン 非ペプチドヒンジ部含有フレキシブル抗体様分子
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
CA2883707A1 (en) * 2012-08-28 2014-03-06 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
IL256833B2 (en) * 2015-07-15 2025-07-01 California Inst Of Techn IL-17F-specific binding agents, compositions and methods of use and preparation
WO2017176769A1 (en) 2016-04-04 2017-10-12 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
CN111557902A (zh) * 2020-07-03 2020-08-21 中国人民解放军总医院 一种负载阿仑膦酸钠的可注射聚乙二醇水凝胶的制备方法与应用
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992005801A1 (en) * 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
AU1674292A (en) * 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
AU762799B2 (en) * 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
WO2001080883A1 (en) * 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
WO2002046208A2 (en) * 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
US20030211078A1 (en) * 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs

Similar Documents

Publication Publication Date Title
US11345736B2 (en) Multi-specific molecules
CN101616691B (zh) 多聚体缀合物
Liu et al. Immobilized antibody orientation analysis using secondary ion mass spectrometry and fluorescence imaging of affinity-generated patterns
Lee et al. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds
Natarajan et al. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals
JP2005539067A (ja) ポリエチレングリコールリンカーを用いる二重特異性分子の産生
JP2019511201A5 (cg-RX-API-DMAC7.html)
JP6865584B2 (ja) 化合物の共有結合性コンジュゲーションのためのmTG基質
JP2011506943A (ja) 識別アッセイ
CN1768266A (zh) 纯化稳定的放射性碘偶联物的方法
US20020197694A1 (en) Conjugates of reduced antibodies and biomolecules
JP2015502547A (ja) 多特異性結合体の遊離結合パートナーの検出方法
Siemers et al. Construction, expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation
Zhao et al. Site-specific modification of a single-chain antibody using a novel glyoxylyl-based labeling reagent
AU2005249553B2 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
FI95579C (fi) Immunologinen menetelmä intaktin prokollageenipeptidin (tyyppi III) ja prokollageenin (tyyppi III) määrittämiseksi selektiivisesti elimistönesteistä ja väline sen toteuttamiseksi
JP2005535898A (ja) 表面官能化のための方法及び試薬
Jones et al. Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of β2GPI and suppression of an anti-β2GPI immune response
Wade et al. Use of thiazolidine-mediated ligation for site specific biotinylation of mouse EGF for biosensor immobilisation
Kuan et al. Solid‐Phase Protein Modifications: Towards Precision Protein Hybrids for Biological Applications
US11421083B2 (en) PETx polymer, preparation method and three-dimensional thorn-like sensor interface
Tai et al. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers
JP3836429B2 (ja) 規定した化学量論の結合体
KR102006997B1 (ko) IgG Fc 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
JP6420281B2 (ja) タンパク質解析用固相担体及びその製造方法